Discovery of ginisortamab, a potent and novel anti-gremlin-1 antibody in clinical development for the treatment of cancer

IF 5.6 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

mAbs Pub Date : 2023-12-12 DOI:10.1080/19420862.2023.2289681

Gareth C. G. Davies, Neesha Dedi, Paul S. Jones, Lara Kevorkian, David McMillan, Cristina Ottone, Monika-Sarah E. D. Schulze, Anthony Scott-Tucker, Roohi Tewari, Shauna West, Michael Wright, Tania F. Rowley

引用次数: 0

Abstract

Gremlin-1, a high-affinity antagonist of bone morphogenetic proteins (BMP)-2, −4, and −7, is implicated in tumor initiation and progression. Increased gremlin-1 expression, and therefore suppressed...

查看原文本刊更多论文

发现吉尼索坦单抗--一种用于治疗癌症的临床开发中的强效新型抗格雷姆林-1 抗体

Gremlin-1是骨形态发生蛋白（BMP）-2、-4和-7的一种高亲和力拮抗剂，与肿瘤的发生和发展有关。Gremlin-1的表达增加，从而抑制了...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

mAbs 工程技术-仪器仪表

CiteScore

10.70

自引率

11.30%

发文量

审稿时长

6-12 weeks

期刊介绍： mAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics.